A Smo mutation, D477G, that prevents Vismodegib from binding to Smo was identified in a medulloblastoma patient who had relapsed after an initial response [40], and another Smo mutation, E518K, has also been identified in humans [41]. This evidence concerns the gene SMO and medulloblastoma.